Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,001)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05371197 | Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer | unknown | Phase 2 | 26 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT05214339 | A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | May 5, 2022 |
| clinicaltrials |
| NCT04460066 | A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma. | unknown | Phase 1 / Phase 2 | 70 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | May 4, 2022 | clinicaltrials |
| NCT05111366 | TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection(ALTER-H006) | unknown | Phase 2 | 37 | Xianhai MaoOTHER | 1 | May 4, 2022 | clinicaltrials |
| NCT05290220 | HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 60 | Shanghai Henlius BiotechINDUSTRY | 0 | May 3, 2022 | clinicaltrials |
| NCT02562963 | Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Minghui ZhangOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT05357196 | PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 68 | SciClone PharmaceuticalsINDUSTRY | 1 | May 2, 2022 | clinicaltrials |
| NCT05353582 | Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases | unknown | Phase 2 | 168 | Sun Yat-sen UniversityOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05354817 | Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin(Re-Play) | unknown | Phase 2 | 25 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT02794337 | TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer(TACE-SBRT) | unknown | Phase 2 / Phase 3 | 67 | Tata Memorial HospitalOTHER_GOV | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05342389 | Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer | unknown | Phase 2 | 68 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT05335460 | To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer | unknown | Phase 2 | 36 | Fujian Cancer HospitalOTHER_GOV | 0 | Apr 19, 2022 | clinicaltrials |
| NCT05171439 | Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples | unknown | Phase 2 | 6 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05327582 | An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC | unknown | Phase 1 / Phase 2 | 65 | Chinese PLA General HospitalOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05322187 | Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy(sPLENTY-pc) | unknown | Phase 2 / Phase 3 | 15 | RenJi HospitalOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05322499 | Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer | unknown | Phase 2 | 80 | Zhejiang Cancer HospitalOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT03940131 | Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR(REPAN) | unknown | Phase 2 | 30 | King Abdullah Medical CityOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03957733 | Phase II/III Study to Assess the Efficacy of Neoadjuvant Consolidation Chemotherapy in Rectal Cancer Patients. | unknown | Phase 2 / Phase 3 | 338 | King Abdullah Medical CityOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05313906 | RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05311189 | Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 0 | Apr 5, 2022 | clinicaltrials |
| NCT05311319 | HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection | unknown | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT03457896 | Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | unknown | Phase 2 | 35 | NSABP Foundation IncNETWORK | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05299411 | Intravenous Iron Infusion on Chemotherapy-induced Anemia | unknown | Phase 2 | 80 | Korea University Guro HospitalOTHER | 0 | Mar 29, 2022 | clinicaltrials |
| NCT05298020 | Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer | unknown | Phase 2 | 20 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT03086993 | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 295 | Delcath Systems Inc.INDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
| NCT05289726 | Study on the Prevention of Dermal Toxicity Caused by Regorafenib by Traditional Chinese Medicine TDX105 | unknown | Phase 2 | 152 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 21, 2022 | clinicaltrials |
| NCT05266820 | Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer | unknown | Phase 2 | 120 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05282433 | Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 45 | Zhongnan HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT04390958 | Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 70 | Chinese Academy of Medical SciencesOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT04119622 | Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer | unknown | Phase 2 | 30 | Aiping ZhouUNKNOWN | 1 | Mar 11, 2022 | clinicaltrials |
| NCT04835402 | Electroporation Potentiated Immunotherapy in Cancer(EPIC-1) | unknown | Phase 2 | 8 | Ole Thorlacius-Ussing, MD, DMSc, Professor of SurgeryOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT05162118 | Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 51 | Zhejiang UniversityOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT04970914 | Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003(ALTER-C003) | unknown | Phase 2 | 32 | Peking Union Medical College HospitalOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT05270889 | Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial | unknown | Phase 2 | 50 | Yonsei UniversityOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03917966 | The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC | unknown | Phase 2 | 80 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT05265962 | Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade | unknown | Phase 2 | 85 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Mar 4, 2022 | clinicaltrials |
| NCT04167436 | Fit for Surgery. Multimodal Prehabilitation in Colorectal Cancer Patients | unknown | Phase 2 / Phase 3 | 48 | Zealand University HospitalOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT04247256 | A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI | unknown | Phase 1 / Phase 2 | 35 | Scandion Oncology A/SINDUSTRY | 3 | Mar 2, 2022 | clinicaltrials |
| NCT03748680 | IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer(IMPROVE-IT) | unknown | Phase 2 | 64 | Karen-Lise Garm SpindlerOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT05257122 | A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer | unknown | Phase 2 | 32 | Fudan UniversityOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT05141747 | A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer. | unknown | Phase 2 | 60 | Shanghai Miracogen Inc.INDUSTRY | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05251662 | Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT04808466 | Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy(WUHIPEC01) | unknown | Phase 2 | 231 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT04845490 | Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy(WUHIPEC02) | unknown | Phase 2 | 201 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Feb 21, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05241899 | A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer | unknown | Phase 2 | 56 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT05240404 | Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma | unknown | Phase 2 | 116 | Xiangya Hospital of Central South UniversityOTHER | 1 | Feb 15, 2022 | clinicaltrials |
Data updated 24 days agoSource updated May 12, 2022source: clinicaltrials